High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). (2018)
Attributed to:
Immunomodulation and Vaccines
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.12688/wellcomeopenres.14691.1
PubMed Identifier: 30175245
Publication URI: http://europepmc.org/abstract/MED/30175245
Type: Journal Article/Review
Volume: 3
Parent Publication: Wellcome open research
ISSN: 2398-502X